10-Q: Nordson Q3 Sales Rise, Net Income Mixed Amid Divestiture

Nordson Corporation reported increased sales and operating profit for the third quarter, driven by acquisitions and strong Advanced Technology Solutions performance, though nine-month net income declined due to higher interest expense and divestiture charges.

Summary

• Sales for the three months ended July 31, 2025, increased by 12.1% to $741.5 million, compared to $661.6 million in the prior year period.
• Sales for the nine months ended July 31, 2025, increased by 4.9% to $2.04 billion, compared to $1.95 billion in the prior year period.
• Net income for the three months ended July 31, 2025, rose 7.2% to $125.8 million, or $2.22 per diluted share, from $117.3 million, or $2.04 per diluted share, in the comparable period.
• Net income for the nine months ended July 31, 2025, decreased 3.6% to $332.8 million, or $5.83 per diluted share, from $345.1 million, or $5.99 per diluted share, in the comparable period.
• Operating profit for the three months increased 12.4% to $187.8 million, while for the nine months, it saw a slight 0.5% increase to $497.5 million.
• Gross margin percentage declined by 1.0% for both the three and nine-month periods, reaching 54.8% and 54.7% respectively.
• Interest expense significantly increased by 39.6% for the three months to $26.3 million and by 31.5% for the nine months to $79.4 million, primarily due to higher average debt levels from acquisitions.
• The company recorded $12.2 million in divestiture and related charges in the third quarter of 2025, including a $4.7 million non-cash impairment charge related to assets held for sale and a $7.5 million charge for the planned closure of a medical contract manufacturing facility.
• Organic sales for the three months increased by 2.1%, with acquisitions contributing 7.8% and currency effects adding 2.2% to total sales growth.
• For the nine months, organic sales decreased by 3.1%, while acquisitions contributed 8.1% and currency effects had a minor negative impact of 0.1%.
• The Advanced Technology Solutions (ATS) segment showed robust organic sales growth of 14.6% for the quarter and 8.0% for the nine months, driven by electronics dispense product lines.
• The Industrial Precision Solutions (IPS) segment experienced organic sales decreases of 2.0% for the quarter and 5.7% for the nine months, primarily due to weaker systems demand in polymer processing.
• The Medical and Fluid Solutions (MFS) segment's organic sales decreased 0.4% for the quarter and 7.1% for the nine months (inclusive of the held-for-sale business), with customer destocking impacting demand in medical interventional solutions.
• The company completed the acquisition of Atrion Corporation on August 21, 2024, for $789.996 million, funded by debt and cash on hand, adding to the MFS segment.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company achieved overall sales and operating profit growth for the quarter, and the ATS segment performed strongly, the nine-month net income decline, increased interest expense, and organic sales weakness in IPS and MFS present challenges. The strategic divestiture and share repurchase program are positive signals, but the mixed financial performance warrants a cautious outlook.

Positives

• Total sales increased by 12.1% for the three months and 4.9% for the nine months, indicating overall revenue growth.
• Operating profit increased by 12.4% for the three months, demonstrating improved operational efficiency in the recent quarter.
• Diluted earnings per share increased by 8.8% for the three months, reflecting stronger profitability in the latest quarter.
• The Advanced Technology Solutions (ATS) segment showed strong organic sales growth of 14.6% for the quarter and 8.0% for the nine months, driven by electronics dispense product lines.
• ATS operating margin improved significantly by 370 basis points for the quarter and 360 basis points for the nine months due to strong conversion on increased organic sales and cost reduction actions.
• The company's liquidity position remains strong, with $147.8 million in cash and cash equivalents and $824.1 million in available borrowing capacity.
• The board of directors authorized an additional $500 million for common share repurchases in August 2025, signaling confidence in the company's value and commitment to shareholder returns.
• The company is in compliance with all debt covenants as of July 31, 2025.

Negatives

• Net income for the nine months decreased by 3.6% to $332.8 million, primarily due to higher interest expense and divestiture charges.
• Diluted earnings per share for the nine months decreased by 2.7% to $5.83.
• Gross margin percentage declined by 1.0% for both the three and nine-month periods, indicating pressure on profitability per sale.
• Interest expense increased significantly by 39.6% for the three months and 31.5% for the nine months, driven by higher average debt levels from acquisitions.
• The company incurred $12.2 million in divestiture and related charges in the third quarter of 2025, impacting profitability.
• Organic sales for the nine months decreased by 3.1%, indicating underlying weakness in some core businesses.
• The Industrial Precision Solutions (IPS) segment experienced organic sales decreases of 2.0% for the quarter and 5.7% for the nine months due to weaker systems demand.
• The Medical and Fluid Solutions (MFS) segment's organic sales decreased 0.4% for the quarter and 7.1% for the nine months (excluding the pending divestiture, organic sales still decreased by 2.3% for the nine months), impacted by customer destocking trends.
• MFS operating margin declined significantly by 510 basis points for the quarter and 460 basis points for the nine months, partly due to restructuring and acquisition-related costs.

Risks

• U.S. and international economic and political conditions could negatively impact financial performance.
• Financial and market conditions, including interest rate fluctuations and credit availability, pose risks.
• Currency exchange rates and devaluations can affect reported financial results.
• Challenges in completing and successfully integrating acquisitions, including Atrion, could impact operations and financial results.
• Difficulty in successfully divesting or disposing of businesses that do not fit the strategic plan could arise.
• Changes in U.S. trade policy and trade agreements, including tariffs, may negatively affect sales, margins, and profitability.
• Changes in tax law could impact the company's financial condition.
• Unforeseen events beyond control, such as political unrest (including conflicts in Europe and the Middle East), acts of terror, natural disasters, and pandemics, could disrupt operations.
• Environmental remediation obligations, such as the New Richmond municipal landfill, could incur greater costs than currently estimated.

Future Outlook

The company's long-term growth strategy is centered on addressing global customer needs. It anticipates the adoption of new accounting standards (ASU 2023-07, ASU 2023-09, ASU 2024-03) in fiscal years 2025, 2026, and 2028, respectively, expecting expanded disclosures but no material impact on consolidated financial statements. The recently signed One Big Beautiful Bill Act (OBBBA) is not expected to materially impact current year consolidated financial statements. The pending sale of select medical contract manufacturing product lines is expected to close no later than the fourth quarter of 2025. Management expects cash from operations, combined with available borrowing capacity and access to capital markets, to be more than adequate to fund liquidity needs for the foreseeable future.

Management Comments

• Our strategy for long-term growth is based on solving customers needs globally.
• The financial results of the Atrion acquisition are not expected to have a material impact on our Consolidated Financial Statements.
• The company is currently evaluating the OBBBAs impact and does not expect it to have a material impact on its current year consolidated financial statements.
• Cash from operations, which, when combined with our available borrowing capacity and ready access to capital markets, is expected to be more than adequate to fund our liquidity needs over the twelve months and the foreseeable future thereafter.
• The Company believes it has the ability to generate and obtain adequate amounts of cash to meet its long-term needs for cash.

Industry Context

The company operates in diverse end markets including packaging, electronics, medical, and industrial sectors. While the Advanced Technology Solutions (ATS) segment, serving electronics and consumer non-durable markets, shows robust growth, the Industrial Precision Solutions (IPS) segment faces weaker systems demand in polymer processing. The Medical and Fluid Solutions (MFS) segment is impacted by customer destocking trends, particularly in medical interventional solutions, indicating a mixed demand environment across its various industrial and medical applications. The divestiture of certain medical contract manufacturing product lines suggests a strategic realignment within the MFS segment to focus on core fluid management solutions.

Comparison to Industry Standards

• Not provided in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in pending or potential litigation regarding environmental, product liability, patent, contract, employee, and other matters arising from the normal course of business.
• The company has voluntarily agreed to share costs associated with the remediation of the City of New Richmond municipal landfill and the construction of a potable water delivery system.

Stakeholder Impact

• Shareholders: Impacted by increased diluted EPS for the quarter but decreased diluted EPS for the nine months. The share repurchase program could be positive for shareholder value.
• Employees: Stephen P. Lovass's separation from the company and the planned closure of a medical contract manufacturing facility will affect employees in those areas.
• Customers: Organic sales declines in IPS and MFS segments suggest fluctuating demand from certain customer bases, while ATS customers show robust demand.
• Creditors: Increased interest expense due to higher debt levels impacts the cost of borrowing, but the company remains in compliance with all debt covenants and has strong liquidity.
• Suppliers: Changes in trade policies and tariffs could negatively impact relationships and costs with suppliers.

Next Steps

• The pending sale of select product lines in the medical contract manufacturing business is expected to close no later than the fourth quarter of 2025.
• The company plans to adopt ASU 2023-07 (Segment Reporting) beginning with its Annual Report on Form 10-K for the fiscal year ending October 31, 2025.
• The company anticipates adopting ASU 2023-09 (Income Taxes) in fiscal 2026.
• The company anticipates adopting ASU 2024-03 (Income Statement) in fiscal 2028.
• The company will continue to fund its share repurchase program using cash from operations and proceeds from borrowings under credit facilities.

Key Dates

Recommendation

Nordson's Q3 results show resilience with overall sales and operating profit growth, largely driven by the ATS segment and recent acquisitions. However, the nine-month net income decline, persistent organic sales weakness in IPS and MFS (even excluding the divestiture), and rising interest expenses are notable concerns. The strategic divestiture of the medical contract manufacturing business, while incurring charges, aims to streamline operations. The ongoing share repurchase program is a positive for shareholder returns. Given the mixed performance, with strong areas offset by challenges in others and increased debt costs, a 'hold' recommendation is appropriate. Investors should monitor organic growth trends across segments and the impact of debt management in future periods.

Keywords

Precision Technology, Dispensing Systems, Adhesives, Coatings, Polymers, Sealants, Biomaterials, Fluid Management, Medical Devices, Electronics Manufacturing, Industrial Solutions, Advanced Technology, SEC Filing, Quarterly Report, Financial Results